EUCTR2016-001219-18-DK进行中（未招募）1 期
Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in ischemic stroke patients - GLP-1 and apoplexia
Herlev Gentofte Hospital0 个研究点目标入组 30 人开始时间: 2016年3月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients = 18 years with new-onset symptoms of stroke
- •Must be able to receive GLP-1 RA / placebo medication within 21 days after the onset of symptoms
- •Radiological verified diagnosis of stroke
- •NIHSS between 1-20 at the onset of symptoms
- •mRS = 2 prior to onset of symptoms
- •Has given written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Intracerebral haemorrhage
- •Subdural / epidural hemorrhage
- •subarachnoid haemorrhage
- •previously major structural damage to the brain (eg. sequelae after large stroke or brain surgery)
- •Type 1 diabetes
- •Type 2 diabetes
- •Known atrial fibrillation
- •> 50% stenosis of halskar
- •Known allergy to GLP-1 RA preparations
- •Hepatic impairment (ALT> 3 x upper normal limit)
- •Renal impairment (eGFR <30 ml / min)
- •Inflammatory bowel disease
- •Previous pancreatitis
- •Heart failure (NYHA class 3-4)
- •Pregnancy or lactation
- •Patient is not expected to co-operate to the investigations
- •Visualization of the middle cerebral artery bilaterally by transcranial doppler not possible
研究者
相似试验
进行中（未招募）
1 期
GLP-1 and persons without stroke.EUCTR2016-001221-14-DKHerlev Gentofte Hospital
已完成
不适用
Effects of Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion and energy balance in human obesity and diabetesutritional, Metabolic, Endocrine: DiabetesNutritional, Metabolic, EndocrineDiabetesISRCTN19339824Record Provided by the NHSTCT Register - 2006 Update - Department of Health6
进行中（未招募）
1 期
iraglutide to Short Bowel Syndrome, a cross-over studyShort bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytesrestricted oral/enteral nutrition to reduce intestinal lossesdisease-related hypophagialack of adaptive hyperphagiaaccelerated gastrointestinal transit timeMedDRA version: 19.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-000825-35-DKRigshospitalet Blegdamsvej16
已完成
1 期
The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.ACTRN12608000428369Royal Adelaide Hospital24
已完成
2 期
Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?Blood GlucoseType-2 DiabetesMetabolic and Endocrine - DiabetesACTRN12610000185066Adam Deane10